The AASLD/IDSA/IAS–USA hepatitis C Guidance addresses management issues ranging from testing and linkage to care, the crucial first steps toward improving health outcomes for HCV-infected persons, to the optimal treatment regimen in particular patient situations. Recommendations are based on evidence and are rapidly updated as new data from peer-reviewed evidence become available. For each treatment
option, recommendations reflect the best possible management for a given patient and a given point of
disease progression. Recommendations are graded with regard to the level of the evidence and strength of the recommendation. The AASLD/IDSA/IAS–USA hepatitis C Guidance is supported by the membershipbased societies and not by pharmaceutical companies or other commercial interests.
Get More Stuff Like This In Your Inbox